ClinicalTrials.Veeva

Find clinical trials for Non-Small-Cell Lung Cancer in Atlanta, GA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Triple Negative Breast Cancer
Colorectal Cancer

Non-Small-Cell Lung Cancer trials near Atlanta, GA, USA:

Status recently updated

HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer

, HER3-DXd will be evaluated in participants with metastatic or unresectable NSCLC with EGFR activating mutation or squamous or non-squamous...

Active, not recruiting
Enrolling
Non-Small Cell Lung Cancer (NSCLC)
Drug: HER3-DXd (FL-DP)
Drug: HER3-DXd (CTM-1 Lyo-DP)

Phase 1

Daiichi Sankyo
Daiichi Sankyo

Atlanta, Georgia, United States and 21 other locations

A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC)

A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: MEDI4736

Phase 2

AstraZeneca
AstraZeneca

Lawrenceville, Georgia, United States and 137 other locations

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Dunwoody, Georgia, United States and 122 other locations

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

This is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in-...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: encorafenib
Drug: binimetinib

Phase 2

Pfizer
Pfizer

Atlanta, Georgia, United States and 157 other locations

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)

of AZD9291 versus a standard of care epidermal growth factor receptor tyrosine kinase inhibitor in patients with locally advanced or Metastatic Non...

Active, not recruiting
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Drug: Erlotinib 150/100 mg
Drug: Placebo Erlotinib 150/100mg

Phase 3

AstraZeneca
AstraZeneca

Atlanta, Georgia, United States and 168 other locations

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously...

Active, not recruiting
Advanced Non Small Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer
Drug: Docetaxel
Drug: MRTX849

Phase 3

Mirati Therapeutics
Mirati Therapeutics

Marietta, Georgia, United States and 227 other locations

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

and safety of osimertinib following chemoradiation in patients with stage III unresectable Epidermal Growth Factor Receptor Mutation Positive non...

Active, not recruiting
Non Small Cell Lung Cancer (Stage III)
Drug: Osimertinib 80mg/40mg
Drug: Placebo Osimertinib 80mg/40mg

Phase 3

AstraZeneca
AstraZeneca

Atlanta, Georgia, United States and 117 other locations

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2)

, early-stage non-small cell lung cancer....

Enrolling
Non-small Cell Lung Cancer
Drug: Cisplatin
Drug: Oleclumab

Phase 2

AstraZeneca
AstraZeneca

Gainesville, Georgia, United States and 94 other locations

Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patient...

Active, not recruiting
Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
Other: Best Standard of Care
Device: NovoTTF-200M device

Phase 3

NovoCure
NovoCure

Atlanta, Georgia, United States and 127 other locations

Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) (EVOKE-02)

or cisplatin), in participants with advanced or metastatic (cancer that has spread) non-small-cell lung ...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Sacituzumab Govitecan-hziy (SG)
Drug: Pembrolizumab

Phase 2

Gilead Sciences
Gilead Sciences

Atlanta, Georgia, United States and 100 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems